Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting

被引：0
|
作者：
Tucker, D. [1 ]
Valentine, W. J. [1 ]
Nielsen, S. [2 ]
Townsend, C. [2 ]
Kotchie, R. [3 ]
Scheijbeler, H. [3 ]
机构：
[1] IMS Hlth, Basel, Switzerland
[2] Novo Nordisk AS, Virum, Denmark
[3] IMS Hlth, London, England
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64978-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A263
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting
    Aristides, M.
    Kotchie, R.
    Nielsen, C.
    Valentine, W. J.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
  • [2] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
    Lynch, M.
    Scheijbeler, H.
    Kotchie, R.
    Neilsen, S.
    White, J.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
  • [3] COST-EFFECTIVENESS OF SWITCHING TO BIPHASIC INSULIN ASPART FROM HUMAN PREMIX INSULIN IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xiao, J.
    Bian, X.
    Zhang, Y.
    Yang, L.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A250 - A250
  • [4] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [6] COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VS. HUMAN PREMIX INSULIN IN TYPE 2 DIABETES FROM THE PAYER'S PERSPECTIVE IN BULGARIA
    Valov, Vasil
    Palmer, James
    Czech, Marcin
    Savova, Alexandra
    Petrova, Guenka
    [J]. BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2012, 26 (02) : 2937 - 2944
  • [7] Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes
    Valentine, William J.
    Pollock, Richard F.
    Plun-Favreau, Juliette
    White, Jeremy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1399 - 1412
  • [8] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    [J]. Advances in Therapy, 2010, 27 : 814 - 827
  • [9] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    [J]. ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [10] Cost-effectiveness analysis of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin plargine in the Swedish setting
    Ray, Joshua A.
    Munro, Vicki
    Brandt, Ann-Sofie
    Valentine, William J.
    Roze, Stephane
    Foos, Volker
    Lurati, Francesco
    Palmer, Andrew J.
    [J]. DIABETES, 2006, 55 : A558 - A558
12345